logo

125I-interleukin-8 radiolabelling and in vivo distribution

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

125I-interleukin-8 radiolabelling and in vivo distribution

FAN Wo
QIAN Jian-Hua
ZHU Ran
NIN Ping
XU Yu-Jie
ZHANG Yi
Nuclear Science and TechniquesVol.15, No.2pp.111-114Published in print 01 Apr 2004
33300

To study the radioiodinating condition of interleukin-8(IL-8) and observe its biodistribution in mice for understanding the possibility of its application in nuclear medicine, we labelled IL-8 with 125I using Bolton-hunter reagent, and the distributions in mice at 5 min, 30 min, 1h, 6h and 24h after injection of 125I –IL-8 were measured. The blood clearance curve was obtained and fitted with the two-compartment model. The results showed that 125I-IL-8 was obtained with a labeling efficiency of 12.2% ±6.5% and a radiochemical purity of 91.4%±6.5%. Its specific activity was 14.8 kBq/μg IL-8. A fast phase half – life T1/2αof 0.32 h and a slow phase half – life T1/2β of 8.01 h were calculated from the blood clearance curve. The uptakes of radioactivities in kidneys and lung had the peaks of 85.87%ID /g and 16.17%ID /g at 30 min after intravenous injection, respectively. The uptakes in liver and spleen were 12.05%ID /g and 8.97%ID /g as the maximum at 5 min after injection. The clearance in blood and other organs was fast. Except for kidneys and lung, 125I –IL-8 was less than 1%ID/ g 24 h after administration. It is concluded that radioiodinated IL-8 is a promising radiopharmaceutical in nuclear medicine, especially for imaging infection. But to enhance the labeling efficiency of radioiodinated IL-8 and to decrease its in vivo deiodination are the subjects necessary to be further investigated.

Interleukin-8125IRadiolabelingBiodistribution
References
[1] Simonet WS, Hughes TM, Nguyen HQ et al. J Clin Invest, 1994, 94: 1310
[2] Li F, Zhang X B, Mizzi C et al. Vet Immunol Immunopathol, 2002, 90: 65
[3] Dunlevy JR, Couchman JR. J Cell Sci, 1995, 108: 311
[4] Frohlich D, Eiber RM, Jochum M et al. Cytokine, 1997, 9: 288
[5] Yoshinaga M, Ohtani A, Tsuruta S et al. Official J Can Ass Gastroent, 2000, 14: 277
[6] Inoue K, Slaton JW, Kim SJ et al. Cancer Res, 2000, 60: 2290
[7] Bohnet S, Kotschau U, Braun J et al. Infection, 1997, 25: 95
[8] Ludwig M, Weidner W, Schaeffer AJ. Urology, 2000, 56: 1025
[9] Conny J, van der Laken CJ, Boerman OC et al. J Nucl Med, 2000, 41: 463
[10] Sartor J, Guhlke S, Tentler M et al. J Nucl Med. 1998, 39(s): 1439-1441
[11] Bohnet S, Kotschau U, Braun J et al. Infection, 1997, 25: 95